GeneNews Ltd (TSE:GEN – Get Free Report) shares rose 7.1% on Monday . The company traded as high as C$0.15 and last traded at C$0.15. Approximately 473,147 shares traded hands during mid-day trading, a decline of 68% from the average daily volume of 1,480,179 shares. The stock had previously closed at C$0.14.
GeneNews Stock Performance
The firm’s fifty day simple moving average is C$0.15. The company has a market capitalization of C$25.49 million and a P/E ratio of -2.21.
GeneNews Company Profile
GeneNews Limited focuses on developing and commercializing proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications. Its proprietary platform technology, the Sentinel Principle, identifies novel biomarkers from whole blood.
Further Reading
- Five stocks we like better than GeneNews
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- Boeing: Why Analysts Think Now’s The Time To Be Brave
- How to buy stock: A step-by-step guide for beginners
- Advanced Micro Devices is Building Momentum with AI: Buy the Dip
- Ride Out The Recession With These Dividend Kings
- Can Evolv Stock Recover From Its Massive Self-Inflicted Drop?
Receive News & Ratings for GeneNews Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeneNews and related companies with MarketBeat.com's FREE daily email newsletter.
